Zymeworks Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $ZYME in the last 7 days.
No SEC Form 4 filings for $ZYME in the last 30 days.
See all $ZYME insider activity →Zymeworks (ZYME) announced that its partner, Jazz Pharmaceuticals (JAZZ), received FDA approval for two Ziihera-containing regimens for treating HER2-positive gastroesophageal adenocarcinoma. This is the second FDA approval for zanidatamab in under two years, validating Zymeworks' Azymetric platform.
Citigroup maintained a Buy rating on Zymeworks (ZYME) and raised its price target to $38.00 from $37.00. The company's GF Value™ is $20.00, suggesting a 47.1% overvaluation. Zymeworks has a GF Score™ of 60, indicating moderate performance. The stock has strong momentum but weak profitability and growth metrics.
Zymeworks Inc (ZYME) shares rose 8% after FDA approval of Jazz Pharmaceuticals' Ziihera, triggering a $250M payment. ZYME's P/S ratio is 59.82x, higher than its historical median. Analysts set price targets at $55 and $40. The company's GF Score is 60, indicating moderate fundamental quality. Insiders sold $4.7M in shares over the past year.
Recent ZYME coverage spans regulation, financial news and market movers.
Positive regulatory news likely to boost Zymeworks' stock on short-term.
Potential modest upside as analysts lift target, but overvaluation concerns remain.
Positive regulatory news likely supports further upside as royalty revenue ramps up.
Positive regulatory approval and milestone payment likely drive near-term price appreciation.
Potential approval could trigger a large cash payment and boost share price.
alphai scores every news story that mentions ZYME with an AI model for sentiment and relevance, and aggregates insider trades from Zymeworks Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Zymeworks (ZYME) announced that its partner, Jazz Pharmaceuticals (JAZZ), received FDA approval for two Ziihera-containing regimens for treating HER2-positive gastroesophageal adenocarcinoma. This is the second FDA approval for zanidatamab in under two years, validating Zymeworks' Azymetric platform.
2 min readCitigroup maintained a Buy rating on Zymeworks (ZYME) and raised its price target to $38.00 from $37.00. The company's GF Value™ is $20.00, suggesting a 47.1% overvaluation. Zymeworks has a GF Score™ of 60, indicating moderate performance. The stock has strong momentum but weak profitability and growth metrics.
1 min readZymeworks Inc (ZYME) shares rose 8% after FDA approval of Jazz Pharmaceuticals' Ziihera, triggering a $250M payment. ZYME's P/S ratio is 59.82x, higher than its historical median. Analysts set price targets at $55 and $40. The company's GF Score is 60, indicating moderate fundamental quality. Insiders sold $4.7M in shares over the past year.
2 min readH.C. Wainwright raised its price target on Zymeworks (ZYME) to $55 from $51, maintaining a Buy rating after FDA approval of Ziihera for HER2-positive gastroesophageal adenocarcinoma. The stock is up 85% over the past year. The approval triggers a $250 million payment from Jazz Pharmaceuticals (JAZZ). Analysts predict 188% revenue growth for FY2026. Zymeworks also announced an acquisition of Theravance Biopharma for $929 million.
2 min readZymeworks (ZYME) shares rose 4% in pre-market trading ahead of an FDA decision on zanidatamab, a HER2-targeting antibody, with a PDUFA target date of August 25, 2026. Approval could trigger a $250 million milestone payment and up to $190 million more in other markets. Analysts have increased price targets ahead of the decision. The company is also pursuing a $929 million acquisition of Theravance Biopharma, expected to close in late 2026.
2 min readZymeworks (ZYME) received FDA approval for Ziihera in treating HER2+ gastroesophageal adenocarcinoma. The drug, licensed to Jazz Pharmaceuticals (JAZZ), qualifies for a $250 million milestone payment, with potential future payments up to $1.3 billion. ZYME shares fell 9.92%, while JAZZ shares rose 3.96%.
2 min readZymeworks Inc. (ZYME) announced FDA approval for Ziihera (zanidatamab-hrii) in combination with chemotherapy, with or without tislelizumab, for first-line HER2+ GEA treatment. This marks the second FDA approval for zanidatamab in under two years, triggering a $250 million milestone payment from Jazz Pharmaceuticals. Zymeworks could receive up to $1.3 billion in additional milestones and royalties from Jazz, and up to $144 million from BeOne Medicines. The approval is based on Phase 3 trial resul
2 min readZymeworks (ZYME) stock rose 4% in pre-market trading ahead of an FDA decision on its HER2-targeting antibody, zanidatamab, which could trigger a $250M milestone payment. Analysts raised price targets, and the company's acquisition of Theravance Biopharma for $929M adds to investor optimism, despite a weak broader market.
2 min readZymeworks Inc. (ZYME) filed an SEC Form 8-K — Results of Operations and Financial Condition. Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results • August 25, 2026 U.S. PDUFA target action date for zanidatamab has potential to unlock a $250 million U.S. approval milestone and up to $190 million in potential additional global regulatory mi
7 min readThe article says Canada’s biotech sector has seen a strong 12-month run, with listed companies raising $2.4 billion on public markets and excluding Apotex’s $1.5 billion June IPO. It highlights several Canadian biotechs, especially AbCellera Biologics, which plans to report key human efficacy results this quarter for a menopause hot-flash treatment. It also notes foreign investors dominate funding.
7 min read
